Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001178913-18-000468 0001321178 XXXXXXXX LIVE 6 Ordinary Shares, par value NIS 1.0 per share 05/29/2025 false 0001684693 M8694L137 Sol-Gel Technologies Ltd 7 Golda Meir St. Weizmann Science Park Ness Tziona L3 7403648 Perry Wildes, Adv. 972-3-607-4444 One Azrieli Center Tel Aviv L3 6701101 0001321178 Moshe Arkin b PF L3 143257 1806856 143257 1806856 1950113 N 65.31 IN Rows (7) (8) (9) (10) and (11): The beneficial ownership of the securities reported herein is described in Items 5(a) and (b). Row 13: Based on 2,785,787 Ordinary Shares outstanding on June 11, 2025, as provided by the Issuer. Y M. Arkin Dermatology Ltd. b WC L3 1806856 1806856 1806856 N 60.52 CO Rows (8) (10) and (11): The beneficial ownership of the securities reported herein is described in Items 5(a) and (b). Row 13: Based on 2,785,787 Ordinary Shares outstanding on June 11, 2025, as provided by the Issuer. Ordinary Shares, par value NIS 1.0 per share Sol-Gel Technologies Ltd 7 Golda Meir St. Weizmann Science Park Ness Tziona L3 7403648 Item 3 of Schedule 13D is hereby amended to add the following paragraph: Moshe Arkin purchased Ordinary Shares on the following dates and at the following prices per share: on May 7, 2025, Mr. Arkin purchased 2,104 Ordinary Shares at a price of $7.50 per share; on May 8, 2025, Mr. Arkin purchased 4,199 Ordinary Shares at an average price of $7.51 per share; on May 9, 2025, Mr. Arkin purchased 2,517 Ordinary Shares at an average price of $7.40 per share; on May 13, 2025, , Mr. Arkin purchased 4,430 Ordinary Shares at a price of $7.41 per share; on May 14, 2025, Mr. Arkin purchased 400 Ordinary Shares at a price of $7.40 per share; and on May 29, 2025, Mr. Arkin purchased 91,472 Ordinary Shares at an average price of $7.30 per share. Item 5 of Schedule 13D is hereby amended and restated as follows: (a) and (b) As of June 11, 2025, Arkin Dermatology owned directly (and therefore is deemed the beneficial owner of) 1,806,856 Ordinary Shares, which represented beneficial ownership of approximately 60.52% of the Company's outstanding Ordinary Shares. Arkin Dermatology has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Ordinary Shares held by Arkin Dermatology. As of June 11, 2025, Mr. Arkin owned directly (and therefore is deemed the beneficial owner of) 143,257 Ordinary Shares, which represented beneficial ownership of approximately 5.14% of the Company's outstanding Ordinary Shares. Mr. Arkin has the sole power to vote, or direct the voting of, and the sole power to dispose of, or direct the disposition of, these Ordinary Shares. In addition, as the sole shareholder and sole director of Arkin Dermatology, Mr. Arkin may be deemed to be the indirect beneficial owner of the 1,806,856 Ordinary Shares beneficially owned by Arkin Dermatology, which represented beneficial ownership of approximately 65.31% of the Company's outstanding Ordinary Shares. Mr. Arkin has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Ordinary Shares held by Arkin Dermatology. The total Ordinary Shares beneficially owned by Mr. Arkin as of June 11, 2025, is 1,950,112, which represented beneficial ownership of 65.31% of the Company's outstanding Ordinary Shares. Except as set forth in this Schedule 13D, to the best knowledge of the Reporting Persons, none of the Reporting Persons has beneficial ownership of, or has engaged in any transaction during the past 60 days in respect of, any Ordinary Shares. No person, other than the Reporting Persons, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares referred to in this Item 5. Percentages set forth in this amended Schedule 13D were calculated based on 2,785,787 Ordinary Shares outstanding on June 11, 2025. Figures were provided by the Issuer. Moshe Arkin /s/ Moshe Arkin Moshe Arkin 06/12/2025 M. Arkin Dermatology Ltd. /s/ Moshe Arkin Moshe Arkin, Director 06/12/2025